Genetically based hypertension generated through interaction of mild hypoalphalipoproteinemia and mild hyperhomocysteinemia

被引:13
作者
Carnicer, Ricardo
Navarro, Maria A.
Arbones-Mainar, Jose M.
Arnal, Carmen
Surra, Joaquin C.
Acin, Sergio
Sarria, Alfonso
Blanco-Vaca, Francisco
Maeda, Nobuyo
Osada, Jesus
机构
[1] Univ Zaragoza, Fac Vet, Dept Bioquim & Biol Mol & Celular, E-50013 Zaragoza, Spain
[2] Univ Zaragoza, Fac Vet, Dept Patol Anim, E-50013 Zaragoza, Spain
[3] Hosp Santa Creu & Sant Pau, Serv Bioquim, Barcelona, Spain
[4] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA
关键词
apolipoproteins; high-density lipoproteins; homocysteine; hypertension; nitric oxide;
D O I
10.1097/HJH.0b013e3281ab6c3d
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Hyperhomocysteinemia and hypoalphalipoproteinemia are two well-reported risk factors for cardiovascular disease. The effects of the synergistic combination of these two factors on vascular function need to be investigated. Methods and results Four groups of male mice were used: a control wild-type group; a group of mice heterozygous for cystathionine R-synthase deficiency; a group of mice heterozygous for apolipoprotein A-I deficiency; and, finally, a group of double heterozygous mice, with both cystathionine P-synthase and apolipoprotein A-I deficiency. To characterize the resulting phenotype, several parameters including plasma apolipoproteins, lipid profiles, homocysteine, blood pressure and aortic protein were analyzed. As expected, our results indicate that double heterozygous mice are a model of mild hypoalphalipoproteinemia and hyperhomocysteinemia. Further, the additive combination of both risk factors resulted in a significant increase in blood pressure compared with control animals (136 +/- 8.0 versus 126 +/- 7.5 mm Hg, P < 0.01) that was not present in single heterozygous mice. The increase in blood pressure was associated with decreased plasma nitric oxide levels, left ventricle hypertrophy and was independent of low-density lipoprotein (LDL) cholesterol, para-oxonase activity and kidney histological changes. Concomitant decreases in levels of apolipoprotein A-IV (APOA-IV) and caveolin-1 content were also found in the double heterozygous group. Conclusions Our findings suggest an additive adverse effect of hypoalphalipoproteinemia and hyperhomocysteinemia on endothelial function to generate clinical hypertension and cardiac muscle hypertrophy mediated by dysregulation in nitric oxide metabolism.
引用
收藏
页码:1597 / 1607
页数:11
相关论文
共 61 条
[11]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155
[12]   Prehypertension is associated with insulin resistance state and not with an initial renal function impairment -: A metabolic syndrome in active subjects in Spain (MESYAS) Registry substudy [J].
Cordero, A ;
Laclaustra, M ;
León, M ;
Grima, A ;
Casasnovas, JA ;
Luengo, E ;
del Rio, A ;
Ferreira, I ;
Alegria, E .
AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (02) :189-196
[13]   Role of endothelial dysfunction in atherosclerosis [J].
Davignon, J ;
Ganz, P .
CIRCULATION, 2004, 109 (23) :27-32
[14]   Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations [J].
de Bree, A ;
van der Put, N ;
Mennen, L ;
Verschuren, WMM ;
Blom, HH ;
Galan, P ;
Bates, CJ ;
Herrmann, W ;
Ullrich, M ;
Dierkes, J ;
Westphal, S ;
Bouter, LM ;
Heine, RJ ;
Stehouwer, CDA ;
Dekker, JM ;
Nijpels, GN ;
Araújo, F ;
Cunha-Ribeiro, LM ;
Refsum, H ;
Vollset, S ;
Nygard, O ;
Ueland, PM .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2005, 59 (04) :480-488
[15]  
DELAMATRE JG, 1983, J LIPID RES, V24, P1578
[16]   Protection against atherogenesis in mice mediated by human apolipoprotein A-IV [J].
Duverger, N ;
Tremp, G ;
Caillaud, JM ;
Emmanuel, F ;
Castro, G ;
Fruchart, JC ;
Steinmetz, A ;
Denefle, P .
SCIENCE, 1996, 273 (5277) :966-968
[17]   Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia [J].
Eberhardt, RT ;
Forgione, MA ;
Cap, A ;
Leopold, JA ;
Rudd, MA ;
Trolliet, M ;
Heydrick, S ;
Stark, R ;
Klings, ES ;
Moldovan, NI ;
Yaghoubi, M ;
Goldschmidt-Clermont, PJ ;
Farber, HW ;
Cohen, R ;
Loscalzo, J .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :483-491
[18]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375
[19]  
Escolà-Gil JC, 1999, CLIN CHEM, V45, P1567
[20]   The endothelial nitric-oxide synthase-caveolin regulatory cycle [J].
Feron, O ;
Saldana, F ;
Michel, JB ;
Michel, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3125-3128